Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma \[per American Joint Committee on Cancer (AJCC) staging system\] that is unresectable or metastatic~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Subject has not been treated by systemic anticancer therapy for unresectable or metastatic melanoma~Exclusion Criteria:~* Subjects with active brain metastases or leptomeningeal metastases~* Subjects with ocular melanoma~* Subjects with active, known or suspected autoimmune disease~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV (Type: EXPERIMENTAL): Specified dose on specified days
- Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV (Type: EXPERIMENTAL): Specified dose on specified days
- Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg (Type: EXPERIMENTAL): Specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).